Fig. 4: The inhibitors for miR-26a/b-5p and IL-6 treatment both rescued the anti-oncogenic effects of DLGAP1-AS1 knockdown. | Cell Death & Disease

Fig. 4: The inhibitors for miR-26a/b-5p and IL-6 treatment both rescued the anti-oncogenic effects of DLGAP1-AS1 knockdown.

From: Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial–mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathway

Fig. 4

a qRT-PCR detected that miR-26a/b-5p levels in Hep G2 cells with DLGAP1-AS1 knockdown were downregulated by transfecting miR-26a/b-5p inhibitors. b ELISA evaluated the efficiency of IL-6 treatment in Hep G2 cells with DLGAP1-AS1 knockdown. c CCK-8 assay showed that both miR-26a/b-5p inhibitors and IL-6 rescued the inhibitory effect on cell proliferation of DLGAP1-AS1 knockdown. d Wound healing assay showed that both miR-26a/b-5p inhibitors and IL-6 rescued the inhibitory effect on cell migration of DLGAP1-AS1 knockdown. e TUNEL assay showed that both miR-26a/b-5p inhibitors and IL-6 rescued the promotional effect on cell apoptosis of DLGAP1-AS1 knockdown. f, g The influences of miR-26a/b-5p knockdown and IL-6 treatment on EMT-related factors in Hep G2 cells with DLGAP1-AS1 knockdown were respectively analyzed using qRT-PCR and WB. All data are presented as the mean ± SD of three independent experiments. *p < 0.05, **p < 0.01.

Back to article page